Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Director | June 10, 2022 | June 28, 2022 |
| NovoCure LtdNVCR · Entity 4494 | Director · Executive Chairman | March 03, 2026 | March 05, 2026 |
| OptiNose, Inc.OPTN · Entity 79464 | Director | June 10, 2020 | June 12, 2020 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,499 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 18,169 · Balance 94,499 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
Minerva Neurosciences, Inc.
Report date June 10, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2032-06-09 | Direct | 2,500 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 2,500 · Balance 2,500 F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year.
F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.
F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
NovoCure Ltd
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 200,000 · Balance 200,000 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 400,284 |
Reported balance
After 2026-03-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-03 · Grant · Acquired 200,284 · Balance 400,284 F2: Represents vesting of performance-based restricted stock units. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 349,727 |
Reported balance
After 2026-03-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-03-03 · Sale · Disposed 50,557 · Balance 349,727 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 328,397 |
Reported balance
After 2026-03-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-03-03 · Sale · Disposed 21,330 · Balance 328,397 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 258,445 |
Reported balance
After 2026-03-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-03 · Grant · Acquired 258,445 · Balance 258,445 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 288,517 |
Reported balance
After 2026-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-03 · Grant · Acquired 30,072 · Balance 288,517 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2: Represents vesting of performance-based restricted stock units.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.
F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.
F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
OptiNose, Inc.
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2030-06-09 | Direct | 14,439 |
Reported balance
After 2020-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-10 · Grant · Acquired 14,439 · Balance 14,439 F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 20:05 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 135,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001193125-26-248249 · ownership.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Class A Common Stock · 135,000 shares Expires 2036-05-28 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 30,072 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001194459-26-000001 · primarydocument.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,517 Underlying: Ordinary Shares · 30,072 shares Expires 2036-03-03 F6 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 258,445 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001194459-26-000001 · primarydocument.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,445 Underlying: Ordinary Shares · 258,445 shares Expires 2036-03-03 F6 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 21,330 | $13.43 | $286,436.30 |
DisclosureSEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,397 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 50,557 | $12.79 | $646,447.08 |
DisclosureSEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,727 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 200,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,284 F2 · security: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:12 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 125,862 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-080261 · ownership.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,862 Underlying: Class A Ordinary Shares · 125,862 shares Expires 2035-05-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:12 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 18,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028153 · form4-12032024_101221.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,499 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:31 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 62,558 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000950170-24-068038 · ownership.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,558 Underlying: Class A Ordinary Shares · 62,558 shares Expires 2034-05-30 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:33 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 15,000 | $16.98 | $254,700.00 |
DisclosureSEC source: 0001415889-24-014279 · form4-05232024_080506.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,330 Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 20:32 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 15,000 | $16.30 | $244,500.00 |
DisclosureSEC source: 0001415889-24-007635 · form4-03122024_080313.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,330 Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 22:33 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 20,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015780 · form4-12042023_101219.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,330 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 13:15 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector Stock Option (right to buy) · Derivative | 48,128 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-23-040419 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,128 Underlying: Class A Ordinary Shares · 48,128 shares Expires 2033-06-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 22:10 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 18,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-011980 · form4-12022022_101236.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,956 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:44 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 837 | $69.66 | $58,304.58 |
DisclosureSEC source: 0001645113-22-000071 · wf-form4_165955946744367.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,176 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:27 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantCommon Units in ProKidney LP · Derivative | 1,514,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012366 · dp177040_4-doyle.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,326 Underlying: Class A Ordinary Shares · 1,514,326 shares Expires not disclosed F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F4 · derivative.exercise_price: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. F4 · derivative.exercise_date: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. F4 · derivative.expiration_date: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:27 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantClass B Ordinary Shares · Derivative | 1,514,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012366 · dp177040_4-doyle.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,326 Underlying: Class A Ordinary Shares · 1,514,326 shares Expires not disclosed F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. F2 · derivative.exercise_price: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.exercise_date: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.expiration_date: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. Read SEC document |
| June 10, 2022 Filed Jun 28, 2022 23:35 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001209191-22-039688 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2032-06-09 F1 · security: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2 · derivative.exercise_price: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · shares: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. F2 · derivative.underlying_shares: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · balance_after: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,385 | $70.10 | $167,188.50 |
DisclosureSEC source: 0001645113-22-000024 · wf-form4_164686246214915.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,013 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 14,581 | $80.59 Strike: $80.59 | $1,175,082.79 |
DisclosureSEC source: 0001645113-22-000018 · wf-form4_164669525357817.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,581 Underlying: Ordinary Shares · 14,581 shares Expires 2032-02-29 F1 · shares: Options to buy 14,581 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:11 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 7,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-010527 · edgar.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,307 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:01 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 995 | $149.38 | $148,631.11 |
DisclosureSEC source: 0001645113-21-000096 · wf-form4_162811081937813.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,398 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:49 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-21-040687 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-10 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 40,000 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2021 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 600 | $216.69 | $130,016.40 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 22 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,393 F22 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 600 shares in multiple trades at prices ranging from $216.57 to $216.79. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $214.67 | $107,332.50 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 21 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,993 F21 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 500 shares in multiple trades at prices ranging from $213.99 to $214.91. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,500 | $213.35 | $320,020.50 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 20 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,493 F20 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,500 shares in multiple trades at prices ranging from $212.95 to $213.72. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 600 | $211.28 | $126,765.60 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 19 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,993 F19 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 600 shares in multiple trades at prices ranging from $211.18 to $211.38. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 521 | $210.18 | $109,504.30 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 18 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,593 F18 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 521 shares in multiple trades at prices ranging from $209.81 to $210.66. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,200 | $209.34 | $460,554.60 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 17 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,114 F17 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 2,200 shares in multiple trades at prices ranging from $208.74 to $209.72. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,500 | $207.80 | $935,118.00 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 16 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,314 F16 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 4,500 shares in multiple trades at prices ranging from $207.20 to $208.20. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,284 | $206.35 | $264,955.97 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 15 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,814 F15 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,284 shares in multiple trades at prices ranging from $206.04 to $207.01. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,600 | $205.43 | $328,689.60 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 14 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,098 F14 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,600 shares in multiple trades at prices ranging from $205.00 to $205.76. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,972 | $204.28 | $402,834.24 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 13 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,698 F13 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,972 shares in multiple trades at prices ranging from $203.96 to $204.90. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,555 | $203.25 | $519,311.42 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 12 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,670 F12 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 2,555 shares in multiple trades at prices ranging from $202.90 to $203.77. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,388 | $202.16 | $887,069.30 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 11 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,225 F11 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 4,388 shares in multiple trades at prices ranging from $201.85 to $202.74. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,125 | $201.55 | $831,377.25 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 10 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,613 F10 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 4,125 shares in multiple trades at prices ranging from $200.85 to $201.84. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,338 | $199.71 | $866,354.99 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 9 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,738 F9 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 4,338 shares in multiple trades at prices ranging from $199.50 to $200.30. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,563 | $198.98 | $2,101,794.05 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 8 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,076 F8 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 10,563 shares in multiple trades at prices ranging from $198.49 to $199.43. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,612 | $197.83 | $2,692,875.57 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 7 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,639 F7 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 13,612 shares in multiple trades at prices ranging from $197.39 to $198.29. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 24,338 | $197.00 | $4,794,659.01 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,251 F6 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 24,338 shares in multiple trades at prices ranging from $196.38 to $197.38. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,814 | $196.07 | $1,728,187.42 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,589 F5 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 8,814 shares in multiple trades at prices ranging from $195.38 to $196.36. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,600 | $194.94 | $311,904.00 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,403 F4 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,600 shares in multiple trades at prices ranging from $194.38 to $195.35. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,090 | $193.57 | $404,563.39 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,003 F3 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 2,090 shares in multiple trades at prices ranging from $193.15 to $194.06. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,900 | $192.52 | $365,795.60 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,093 F2 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,900 shares in multiple trades at prices ranging from $192.00 to $193.00. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,400 | $191.26 | $267,768.20 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,993 F1 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,400 shares in multiple trades at prices ranging from $191.00 to $191.95. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,928 | $134.12 | $1,063,303.36 |
DisclosureSEC source: 0001645113-21-000049 · wf-form4_161739444210734.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,393 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 9,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000049 · wf-form4_161739444210734.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,259 | $125.25 | $1,159,689.75 |
DisclosureSEC source: 0001645113-21-000049 · wf-form4_161739444210734.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 21:51 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 896 | $76.39 | $68,443.65 |
DisclosureSEC source: 0001645113-20-000113 · wf-form4_159649143693903.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,062 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.